Virometix Closes Financing Round
Schlieren, Switzerland (May 19, 2017)
– Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector.
> View complete release
> Download PDF release Virometix plans to use the new funds to expand its operations and progress its vaccine candidates for infectious and viral diseases and cancer to next inflections points, including the start of a phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent safety and strong efficiency in preclinical models. The financing round was substantially oversubscribed.
Dr Pierre A. Morgon, Chairman of the Board, said: “With this infusion of smart capital from investors experienced in healthcare, and the network of world-class experts supporting the company, Virometix is ideally positioned to leverage its attractive platform with its strong intellectual property position”.
“We are delighted to have received substantial support from our shareholders as well as several new private investors, said Arin Ghasparian, CEO of Virometix, „The new financing will enable us to advance our lead RSV vaccine candidate more rapidly into clinical development, to further define our solution in oncology immunotherapy, and further underpins the attractiveness of our value proposition. “
Emmanuel Savioz, recently appointed CFO, commented “This financing provides the resources we need to reach important value-inflection milestones in 2018 and beyond.”